An Intelligent Evolution for Dako and Cytomation
Executive Summary
The Dako-Cytomation merger gives both companies things they've wanted for some time. Denmark-based Dako, a leading global supplier of IHC reagents and systems, gets a solid instrument platform and a stronger presence in the US. US-based Cytomation, an aggressive maker of high-speed flow cytometry instruments, gets a world-class marketing partner and a high-quality reagent house. The businesses complement each other, with almost no redundancies, say both companies' CEOs.
You may also be interested in...
Going With the Flow
In the in vitro diagnostics world, flow cytometry is a highly specialized, labor intensive niche, aimed at sophisticated analysis of intact whole cells. Dako Cytomation was formed in July to try to make inroads into this field, which some see as an area poised for growth. The merger of Dako and Cytomation, however, has infuriated Dako's former partner, Partec, a small German company focused on industrial applications of flow. Partec, however, is coming up with a new strategy for expanding its limited presence in human healthcare.
Going With the Flow
In the in vitro diagnostics world, flow cytometry is a highly specialized, labor intensive niche, aimed at sophisticated analysis of intact whole cells. Dako Cytomation was formed in July to try to make inroads into this field, which some see as an area poised for growth. The merger of Dako and Cytomation, however, has infuriated Dako's former partner, Partec, a small German company focused on industrial applications of flow. Partec, however, is coming up with a new strategy for expanding its limited presence in human healthcare.
Targeted Therapeutics: Linking EGF Receptor Drugs to Diagnostics
Herceptin-HerceptTest is a successful model of the benefits of linking a therapeutic to a diagnostic test, but the ties aren't as clear-cut in the next crop of targeted therapies to come to market. EGF receptor-based drugs work on specific receptor targets in a variety of cancers, but scientists haven't been able so far to correlate patient response to the drugs to receptor presence or quantity. Yet the issue is extremely important, both to pharma companies seeking to determine how they will design their clinical trials and submit data to the FDA and to diagnostic companies looking for a new kind of market.